Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease

Michelle M. Mielke, Matthew Anderson, J. Wesson Ashford, Andreas Jeromin, Pei Jung Lin, Allyson Rosen, Jamie Tyrone, Lawren VandeVrede, Deanna Willis, Oskar Hansson, Ara S. Khachaturian, Suzanne E. Schindler, Joan Weiss, Richard Batrla, Sasha Bozeat, John R. Dwyer, Drew Holzapfel, Daryl Rhys Jones, James F. Murray, Katherine A. PartrickEmily Scholler, George Vradenburg, Dylan Young, Joel B. Braunstein, Samantha C. Burnham, Fabricio Ferreira de Oliveira, Yan Helen Hu, Soeren Mattke, Zul Merali, Mark Monane, Marwan Noel Sabbagh, Eli Shobin, Michael W. Weiner, Chinedu T. Udeh-Momoh

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.

Original languageEnglish
Pages (from-to)8209-8215
Number of pages7
JournalAlzheimer's and Dementia
Volume20
Issue number11
DOIs
StatePublished - Nov 2024

Keywords

  • Alzheimer's disease
  • amyloid
  • biomarker
  • blood-based biomarkers
  • clinical implementation
  • clinical practice
  • cognitive impairment
  • disease-modifying treatment
  • ethics
  • patient journey
  • primary care
  • secondary care

Fingerprint

Dive into the research topics of 'Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this